Back to top
more

Teleflex (TFX)

(Real Time Quote from BATS)

$124.19 USD

124.19
112,805

-1.61 (-1.28%)

Updated Sep 19, 2025 12:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift

by Zacks Equity Research

Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q3.

Zacks Equity Research

Teleflex Hits New 52-Week High: What's Driving the Rally?

by Zacks Equity Research

Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.

Zacks Equity Research

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.

Zacks Equity Research

Teleflex (TFX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 8.00% and 0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More

by Urmimala Biswas

Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.

Zacks Equity Research

Teleflex (TFX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock Now

by Zacks Equity Research

Investor confidence is still high on Teleflex (TFX), thanks to solid prospects.

Zacks Equity Research

Teleflex (TFX) Up 0.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve

by Zacks Equity Research

Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.

Zacks Equity Research

Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve

by Zacks Equity Research

Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.

Zacks Equity Research

Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 2.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.

Zacks Equity Research

GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.

Zacks Equity Research

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View

by Zacks Equity Research

Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.

Zacks Equity Research

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

by Zacks Equity Research

Omnicell (OMCL) aims at product innovation through R&D.

Zacks Equity Research

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.

Zacks Equity Research

Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.

Zacks Equity Research

Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand

by Zacks Equity Research

It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.

Zacks Equity Research

ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.

Zacks Equity Research

LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.

Zacks Equity Research

Teleflex (TFX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Align Technology (ALGN) Beats on Q2 Earnings, Margins Fall

by Zacks Equity Research

We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies.

Zacks Equity Research

Integra Lifesciences' (IART) Earnings Top Estimates in Q2

by Zacks Equity Research

We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.

Zacks Equity Research

Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View

by Zacks Equity Research

Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.